AU2007346587C1 - Methods for the treatment of Senile Dementia of the Alzheimer's Type - Google Patents

Methods for the treatment of Senile Dementia of the Alzheimer's Type Download PDF

Info

Publication number
AU2007346587C1
AU2007346587C1 AU2007346587A AU2007346587A AU2007346587C1 AU 2007346587 C1 AU2007346587 C1 AU 2007346587C1 AU 2007346587 A AU2007346587 A AU 2007346587A AU 2007346587 A AU2007346587 A AU 2007346587A AU 2007346587 C1 AU2007346587 C1 AU 2007346587C1
Authority
AU
Australia
Prior art keywords
alkyl
acyl
sdat
glycerol
plasmanyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007346587A
Other languages
English (en)
Other versions
AU2007346587A1 (en
AU2007346587B2 (en
Inventor
Dayan Goodenowe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Med-Life Discoveries Lp
Original Assignee
Med Life Discoveries Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Med Life Discoveries Lp filed Critical Med Life Discoveries Lp
Publication of AU2007346587A1 publication Critical patent/AU2007346587A1/en
Priority to AU2014201707A priority Critical patent/AU2014201707B2/en
Publication of AU2007346587B2 publication Critical patent/AU2007346587B2/en
Application granted granted Critical
Publication of AU2007346587C1 publication Critical patent/AU2007346587C1/en
Assigned to MED-LIFE DISCOVERIES LP reassignment MED-LIFE DISCOVERIES LP Request for Assignment Assignors: PHENOMENOME DISCOVERIES INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
AU2007346587A 2007-02-08 2007-08-27 Methods for the treatment of Senile Dementia of the Alzheimer's Type Active AU2007346587C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014201707A AU2014201707B2 (en) 2007-02-08 2014-03-21 Methods for the treatment of Senile Dementia of the Alzheimer's Type

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88888307P 2007-02-08 2007-02-08
US60/888,883 2007-02-08
PCT/CA2007/001472 WO2008095275A1 (en) 2007-02-08 2007-08-27 Methods for the treatment of senile dementia of the alzheimer's type

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014201707A Division AU2014201707B2 (en) 2007-02-08 2014-03-21 Methods for the treatment of Senile Dementia of the Alzheimer's Type

Publications (3)

Publication Number Publication Date
AU2007346587A1 AU2007346587A1 (en) 2008-08-14
AU2007346587B2 AU2007346587B2 (en) 2014-03-27
AU2007346587C1 true AU2007346587C1 (en) 2015-01-22

Family

ID=39537686

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007346587A Active AU2007346587C1 (en) 2007-02-08 2007-08-27 Methods for the treatment of Senile Dementia of the Alzheimer's Type

Country Status (8)

Country Link
US (5) US9034923B2 (enExample)
EP (2) EP2117527B1 (enExample)
JP (1) JP5470050B2 (enExample)
AU (1) AU2007346587C1 (enExample)
CA (2) CA2695167C (enExample)
IL (1) IL200029A0 (enExample)
SG (1) SG173418A1 (enExample)
WO (1) WO2008095275A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007346587C1 (en) 2007-02-08 2015-01-22 Med-Life Discoveries Lp Methods for the treatment of Senile Dementia of the Alzheimer's Type
TWI475989B (zh) * 2008-12-22 2015-03-11 Phenomenome Discoveries Inc 縮醛磷脂類化合物，含彼之醫藥組成物以及治療老化疾病的方法
US10024857B2 (en) 2009-10-01 2018-07-17 Med-Life Discoveries Lp Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020056418A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
CN114236019B (zh) * 2022-02-24 2022-05-06 宝枫生物科技（北京）有限公司 脑白质病变的生物标志物的应用
CN118512461A (zh) * 2024-06-03 2024-08-20 东莞市第八人民医院（东莞市儿童医院） 一种母乳来源磷脂在防治支气管肺发育不良的应用
CN119876292B (zh) * 2025-03-27 2025-06-03 浙江省白马湖实验室有限公司 一种酰胺类缩醛磷脂化合物的制备方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009371A1 (en) 1992-10-09 1994-04-28 Massachusetts Institute Of Technology Antemortem diagnostic test for alzheimer's disease
FR2736265B1 (fr) 1995-07-07 1997-09-26 Forgeot Marcel Nouvelles compositions a base de phosphoglycero ethers et leur utilisation dans le traitement des maladies neuro-degeneratives
US5731354A (en) 1996-05-06 1998-03-24 Clarion Pharmaceuticals Inc. Treatment for the inhibition of neuro-degenerative disease states
US6177476B1 (en) 1998-08-27 2001-01-23 Clarion Pharmaceuticals Inc. Nutritional supplements for replenishing plasmalogens
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
WO2001078652A2 (en) 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
WO2002021139A2 (en) 2000-09-08 2002-03-14 Oxford Glycosciences (Uk) Ltd. Automated identification of peptides
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
DE10291524D2 (de) 2001-04-06 2004-07-01 Anker Thorsten Verfahren zum Nachweis chronisch-demenzieller Erkrankungen, zugehörige Peptide und Nachweisreagenzien
DE10291986D2 (de) 2001-05-09 2004-04-15 Biovision Ag Verfahren zum Nachweis einer progredienten, chronisch-demenziellen Erkrankung, zugehörige Peptide und Nachweisreagenzien
WO2003081506A2 (en) 2002-03-22 2003-10-02 Phenomenome Discoveries Inc. Method of visualizing non-targeted metabolomic data generated from fourier transform ion cyclotron resonance mass spectrometers
JP2004026803A (ja) * 2002-03-29 2004-01-29 Nof Corp 神経細胞死予防剤
CA2746000C (en) 2002-08-23 2014-10-21 Bayer Schering Pharma Aktiengesellschaft Biomarkers for diagnosing alzheimer's disease
SE0203886D0 (sv) * 2002-12-27 2002-12-27 Ltp Lipid Technologies Provide Glycerolesterprodukt och dess användning
US20040191294A1 (en) * 2003-03-27 2004-09-30 Ramaprasad Talahalli Ravichandra Health composition
JPWO2004093910A1 (ja) 2003-04-22 2006-07-13 アステラス製薬株式会社 ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
US7794948B2 (en) 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
WO2005085838A2 (en) 2004-03-02 2005-09-15 Vanderbilt University Computational analysis of mass spectroscopic lipid data
WO2005116659A2 (en) 2004-05-18 2005-12-08 Neurodx, Llc Compositions and methods relating to alzheimer’s disease
WO2007002285A2 (en) * 2005-06-21 2007-01-04 The Trustees Of The University Of Pennsylvania Methods for treating neurological and psychiatric conditions
JP4176749B2 (ja) 2005-07-29 2008-11-05 学校法人帝京大学 疾病検査法
CA2772688A1 (en) 2005-09-12 2007-03-22 Phenomenome Discoveries Inc. Methods for the diagnosis of colorectal cancer and ovarian cancer health states
US20090057553A1 (en) 2005-09-15 2009-03-05 Phenomenome Discoveries Inc. Method and apparatus for fourier transform ion cyclotron resonance mass spectrometry
CA2689848A1 (en) * 2006-02-28 2007-09-07 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
EP3231789A1 (en) 2006-05-26 2017-10-18 Phenomenome Discoveries Inc. Biomarkers for diagnosing multiple sclerosis, and methods thereof
WO2008093709A1 (ja) 2007-01-30 2008-08-07 Tohoku University アミロイド蛋白質の凝集抑制および分解促進によりアミロイドーシスと関連する疾患を予防または治療するための組成物
AU2007346587C1 (en) 2007-02-08 2015-01-22 Med-Life Discoveries Lp Methods for the treatment of Senile Dementia of the Alzheimer's Type
US8026099B2 (en) 2007-07-26 2011-09-27 Washington University Lipid profile as a biomarker for early detection of neurological disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nagan, Narasimhan et al. "Plasmalogens: biosynthesis and functions" Progress in Lipid Research (2001) Vol.40 pages 199 to 220 *

Also Published As

Publication number Publication date
EP2620147B1 (en) 2020-06-03
US20120129934A1 (en) 2012-05-24
CA2620274A1 (en) 2008-06-20
EP2620147A3 (en) 2013-10-02
EP2117527A4 (en) 2012-09-12
US20150306057A1 (en) 2015-10-29
US9517222B2 (en) 2016-12-13
US20130046016A1 (en) 2013-02-21
EP2117527B1 (en) 2020-06-17
CA2620274C (en) 2011-10-04
AU2007346587A1 (en) 2008-08-14
US20160015673A1 (en) 2016-01-21
WO2008095275A1 (en) 2008-08-14
US9034923B2 (en) 2015-05-19
IL200029A0 (en) 2010-04-15
AU2007346587B2 (en) 2014-03-27
US20170056363A1 (en) 2017-03-02
CA2695167C (en) 2011-11-01
EP2117527A1 (en) 2009-11-18
US8993623B2 (en) 2015-03-31
JP2010518029A (ja) 2010-05-27
US10123989B2 (en) 2018-11-13
SG173418A1 (en) 2011-08-29
JP5470050B2 (ja) 2014-04-16
CA2695167A1 (en) 2008-06-20
EP2620147A2 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
AU2007346587C1 (en) Methods for the treatment of Senile Dementia of the Alzheimer's Type
Goodenowe et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia
Mielke et al. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease
Henriques et al. Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase
EP2706992B1 (en) Anxiolytic effect of pterostilbene
US11963939B2 (en) Use of N-acetylcysteine to treat central nervous system disorders
Emekli-Alturfan et al. The emerging relationship between vitamin K and neurodegenerative diseases: a review of current evidence
WO2014144776A1 (en) Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
Phillips et al. The long and the short of Huntington’s disease: how the sphingolipid profile is shifted in the caudate of advanced clinical cases
Farias et al. Lipid mediators in cerebral spinal fluid of traumatic brain injured patients
Song et al. Effects of dietary glucocerebrosides from sea cucumber on the brain sphingolipid profiles of mouse models of Alzheimer's disease
Yu et al. Membrane aging as the real culprit of Alzheimer’s disease: modification of a hypothesis
Nishiyama et al. Homostachydrine is a xenobiotic substrate of OCTN1/SLC22A4 and potentially sensitizes pentylenetetrazole-induced seizures in mice
Santoro et al. L-Carnitine protects mammalian cells from chromosome aberrations but not from inhibition of cell proliferation induced by hydrogen peroxide
Wood et al. Plasmalogen deficit: a new and testable hypothesis for the etiology of Alzheimer’s disease
Chang et al. Parapyruvate, an impurity in pyruvate supplements, induces senescence in human fibroblastic Hs68 cells via inhibition of the α-ketoglutarate dehydrogenase complex
AU2014201707B2 (en) Methods for the treatment of Senile Dementia of the Alzheimer's Type
HK1182935A (en) Compounds for lowering cholesterol
Sibomana et al. Influence of myo-inositol plus ethanolamine on plasmalogens and cell viability during oxidative stress
HK1182935B (en) Compounds for lowering cholesterol
HK1131348B (en) Compounds for use in the treatment of senile dementia of the alzheimer's type
HK1131348A (en) Compounds for use in the treatment of senile dementia of the alzheimer's type
Saitoh et al. Changes in the amounts of myelin lipids and molecular species of plasmalogen PE in the brain of an autopsy case with d-bifunctional protein deficiency
Garcia Heredia Influence of paraoxonase-1 deficiency on metabolic alterations and inflammation
Di et al. A platform for the analysis of metabolites in endocannabinoids-related pathways.

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JUL 2014 .

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 JUL 2014

PC Assignment registered

Owner name: MED-LIFE DISCOVERIES LP

Free format text: FORMER OWNER(S): PHENOMENOME DISCOVERIES INC.